Multiple Sclerosis Clinical Trials in Chicago, Illinois

13 studies are recruiting for multiple sclerosis in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

2. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

   The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

   Stage

   Not phased

   Ages

   18 and older

   Site

   TG Therapeutics Investigational Trial Site, Chicago, Illinois

   Locations

   109 in total

   Run by

   TG Therapeutics, Inc.

   See if you can join NCT06433752 on ClinicalTrials.gov

3. Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain

   The purpose of this study is to to explore the safety and efficacy of the EXOPULSE Mollii suit, a full-body electrostimulation suit, for individuals with neurological or neuromuscular conditions that cause spasticity, hyperreflexia, and/or pain.

   Stage

   Not phased

   Ages

   18 to 75

   Site

   Shirley Ryan AbilityLab, Chicago, Illinois

   Run by

   Shirley Ryan AbilityLab

   See if you can join NCT07132775 on ClinicalTrials.gov

4. Ocrevus Zunovo for MS: Mixed Methods

   Ocrevus Zunovo implementation, feasibility, acceptability, patient satisfaction, treatment persistence, and impact on MS disease outcomes will be analyzed in this mixed methods study. This study will incorporate clinical data and questionnaire results from MS patients who take Ocrevus Zunovo as wel…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Northwestern Memorial Hospital, Chicago, Illinois

   Run by

   Northwestern University

   See if you can join NCT07710105 on ClinicalTrials.gov

5. Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device

   Approximately 50% of people with multiple sclerosis (MS) use a wheelchair within 30 years of the initial diagnosis. Wheelchair use in MS is often associated with fatigue as a consequence of muscle weakness. Indeed, fatigue, a prevalent consequence of MS, often becomes debilitating and exhausts ener…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Illinois at Chicago, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT06410261 on ClinicalTrials.gov

6. Functional Balance Intervention in Multiple Sclerosis

   This project involves two sub-parts: Study 1: Effect of lab-based Functional Balance Intervention (FBI) for physical and cognitive symptoms of Multiple Sclerosis. Study 2: Feasibility of home-based FBI for physical and cognitive symptoms of Multiple Sclerosis. Each study involves a 2-arm, Phase-1, …

   Stage

   Not phased

   Ages

   18 to 90

   Site

   University of Illinois at Chicago, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT06341023 on ClinicalTrials.gov

7. Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

   The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 …

   Stage

   Not phased

   Ages

   18 to 64

   Site

   University of Illinois at Chicago, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT05051618 on ClinicalTrials.gov

8. Nomad P-KAFO Study

   The goal of this clinical trial is to evaluate the impact of using the Nomad powered KAFO in people who have had a musculoskeletal or neurological injury that has affected their ability to walk. The main questions it aims to answer are to quantify the effectiveness of the Nomad in improving mobilit…

   Stage

   Not phased

   Ages

   18 to 89

   Site

   Shirley Ryan AbilityLab, Chicago, Illinois

   Run by

   Shirley Ryan AbilityLab

   See if you can join NCT05644522 on ClinicalTrials.gov

9. Intermittent Hypoxia in Persons With Multiple Sclerosis

   This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are sim…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   Shirley Ryan AbilityLab, Chicago, Illinois

   Run by

   Shirley Ryan AbilityLab

   See if you can join NCT06276634 on ClinicalTrials.gov

10. People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

    The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of int…

    Stage

    Not phased

    Ages

    18 to 70

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT07207148 on ClinicalTrials.gov

11. Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of ~12 months. 2. study the…

    Stage

    Phase 4

    Ages

    18 to 70

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT07225361 on ClinicalTrials.gov

12. Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

    This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found…

    Stage

    Not phased

    Ages

    18 to 75

    Site

    Shirley Ryan AbilityLab, Chicago, Illinois

    Run by

    Shirley Ryan AbilityLab

    See if you can join NCT06390930 on ClinicalTrials.gov

13. Home Based Functional Balance Intervention for Multiple Sclerosis

    The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS). Combined Spe…

    Stage

    Not phased

    Ages

    40 to 90

    Site

    University of Illinois at Chicago, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT07355387 on ClinicalTrials.gov